[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lexeo Therapeutics Inc (LXEO)

Lexeo Therapeutics Inc (LXEO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 387,113
  • Shares Outstanding, K 78,522
  • Annual Sales, $ 0 K
  • Annual Income, $ -99,960 K
  • EBIT $ -98 M
  • EBITDA $ -97 M
  • 60-Month Beta 1.38
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.67

Options Overview Details

View History
  • Implied Volatility 473.89% (+3.20%)
  • Historical Volatility 80.34%
  • IV Percentile 80%
  • IV Rank 40.23%
  • IV High 1,059.77% on 03/24/26
  • IV Low 79.58% on 08/18/25
  • Expected Move (DTE 26) 0.00 (0.00%)
  • Put/Call Vol Ratio 1.42
  • Today's Volume 109
  • Volume Avg (30-Day) 53
  • Put/Call OI Ratio 0.39
  • Today's Open Interest 1,201
  • Open Int (30-Day) 620
  • Expected Range 4.93 to 4.93

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.31
  • Number of Estimates 4
  • High Estimate $-0.25
  • Low Estimate $-0.36
  • Prior Year $-0.60
  • Growth Rate Est. (year over year) +48.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.03 +22.33%
on 06/11/26
5.41 -8.79%
on 05/22/26
+0.22 (+4.67%)
since 05/18/26
3-Month
4.03 +22.33%
on 06/11/26
7.01 -29.72%
on 04/17/26
-0.83 (-14.34%)
since 03/18/26
52-Week
3.60 +36.94%
on 07/25/25
10.99 -55.14%
on 12/23/25
+0.69 (+16.27%)
since 06/18/25

Most Recent Stories

More News
Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia

Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies SUNRISE-FA 2 pivotal study for LX2006 on track to initiate in...

LXEO : 4.93 (-1.00%)
Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia

SUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, inclusion criteria focused on abnormal baseline LVMI and open-label trial design  BLA supportive manufacturing...

LXEO : 4.93 (-1.00%)
Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today...

LXEO : 4.93 (-1.00%)
Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights

SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026; Awaiting final FDA feedback Multiple presentations highlighting progress across cardiac genetic medicine...

LXEO : 4.93 (-1.00%)
Lexeo Therapeutics Reports Monday With Insiders Already Reducing Stakes

Barchart Research What to Expect from LXEO Earnings LXEO Generated May 8, 2026 Current Price $5.83 EPS Estimate $$-0.29 Consensus Rating Strong Buy Average Move 8.80% Lexeo Therapeutics Reports Monday...

LXEO : 4.93 (-1.00%)
Lexeo Therapeutics Reports Monday With Insiders Already Reducing Stakes

Barchart Research What to Expect from LXEO Earnings LXEO Generated May 8, 2026 Current Price $5.83 EPS Estimate $$-0.29 Consensus Rating Strong Buy Average Move 8.80% Lexeo Therapeutics Reports Monday...

LXEO : 4.93 (-1.00%)
Lexeo Therapeutics Reports Monday With Insiders Already Reducing Stakes

Barchart Research What to Expect from LXEO Earnings LXEO Generated May 8, 2026 Current Price $5.83 EPS Estimate $$-0.29 Consensus Rating Strong Buy Average Move 8.80% Lexeo Therapeutics Reports Monday...

LXEO : 4.93 (-1.00%)
Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced...

LXEO : 4.93 (-1.00%)
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026 following Type B meeting; study initiation on track for 1H 2026 First CMC Development and Readiness...

LXEO : 4.93 (-1.00%)
LXEO's Cardiac Gene Therapy Data Finally Arrives: The Pivot Wall Street Demanded or Another Clinical Stall?

Barchart Research What to Expect from LXEO Earnings LXEO Generated March 28, 2026 Current Price $5.46 EPS Estimate $-0.32 Consensus Rating Strong Buy Average Move 8.90% LXEO's Cardiac Gene Therapy Data...

LXEO : 4.93 (-1.00%)

Business Summary

Lexeo Therapeutics is a clinical-stage genetic medicine company which defined cardiovascular diseases and APOE4-associated Alzheimer's disease are treated. Lexeo Therapeutics is based in New York City.

See More

Key Turning Points

3rd Resistance Point 5.63
2nd Resistance Point 5.48
1st Resistance Point 5.21
Last Price 4.93
1st Support Level 4.79
2nd Support Level 4.64
3rd Support Level 4.37

See More

52-Week High 10.99
Fibonacci 61.8% 8.17
Fibonacci 50% 7.30
Fibonacci 38.2% 6.42
Last Price 4.93
52-Week Low 3.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.